The ex vivo production of ammonia predicts l-asparaginase biological activity in children with acute lymphoblastic leukemia

• DOI: 10.1007/s12185-009-0419-x
• Publication Date: 2009-09-18T04:12:41Z
• Authors: Shizuka Watanabe; Kumiko Miyake; Chitose Ogawa; Haruna Matsumoto; Kenichi Yoshida; Shinsuke Hirabayashi; Daisuke Hasegawa; Tadao Inoue; Junko Kizu; Reiko Machida; Akira Ohara; Ryota Hosoya; Atsushi Manabe
• Keywords: Ex vivo; Asparaginase; Ammonia production

Patients with acute lymphoblastic leukemia (ALL), who develop antiasparaginase antibodies without clinical allergic reactions ("silent inactivation") during L: -asparaginase (L: -Asp) treatment, have poor outcomes. Ammonia is produced by hydrolysis of asparagine by L: -Asp. We postulated that plasma ammonia level might reflect the biological activity of L: -Asp. Five children with ALL treated according to the Tokyo Children's Cancer Study Group (TCCSG) protocol were enrolled. Plasma ammonia levels were analyzed immediately and 1 h after incubation at room temperature and "ex vivo ammonia production" was defined as increase in ammonia concentration. Ex vivo ammonia production well correlated with L: -Asp activity (r = 0.882, P < 0.01, n = 23). It always exceeded 170 microg/dL (170-345 microg/dL) in induction therapy. We found 3 patients whose ammonia production was negligible during later phases of therapy. Antiasparaginase antibody was detected and L: -Asp activity decreased in these patients. Ex vivo ammonia production is a surrogate marker of L: -Asp biological activity.